Detail akcie Sanara MedTech Rg online

Business Summary: Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sanara Medtech Inc revenues increased 25% to $75.6M. Net loss before extraordinary items decreased 14% to $4.7M. Revenues reflect Sanara Surgical segment increase of 18% to $49.2M, THP segment increase from $0K to $27K. Lower net loss reflects Depreciation decrease of 66% to $133K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.55.